Quick Read

• Johnson & Johnson (JNJ) reported Q1 revenue of $24.06B, up 9.9% year over year, with adjusted EPS of $2.70 beating consensus for the fourth consecutive quarter, while oncology drugs CARVYKTI jumped 62.1% to $597M and RYBREVANT surged 82.7%, offsetting a 59.7% decline in STELARA from biosimilar competition.

• Johnson & Johnson’s oncology pipeline strength and planned separation of its Orthopaedics business are creating a path to double-digit growth by decade-end, offsetting legacy drug erosion and supporting a 90% confidence buy rating with a $252.01 price target implying 9.37% upside.

• The analyst who called NVIDIA in 2010 just named his top 10 stocks and Johnson & Johnson wasn’t one of them. Get them here FREE.

…